Advik Laboratories Ltd.
BSE: ADVIKLA · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Advik Laboratories Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
MPS Pharmaa Limited is an Indian pharmaceutical company engaged in the manufacturing and marketing of diverse pharmaceutical formulations, including ethical, generic, and over-the-counter products. Its portfolio covers therapeutic segments such as antibacterials, analgesics, and nutritional supplements, produced at its facility in Sohna, Haryana.
Business Model
The company generates revenue through the production and distribution of pharmaceutical formulations in various forms, including tablets, capsules, and liquids. It focuses on domestic distribution while actively exploring export opportunities in emerging markets.
Management Commentary
The company has recently undergone corporate restructuring and a name change to better align its operations with evolving business strategies within the healthcare sector.
Growth Outlook
Growth is expected to be driven by the company's strategic realignment and the expansion of its product reach into emerging international markets. Continued focus on its core therapeutic segments remains central to its operational strategy.
Key Risks
- Regulatory Compliance. The company faces risks associated with maintaining national regulatory standards at its manufacturing facility.
- Market Competition. The Indian pharmaceutical sector is highly competitive, which may impact pricing power and market share for generic and OTC products.
- Execution Risk. Successful implementation of the recent corporate restructuring is critical to achieving the company's long-term strategic objectives.
Start your research today
Unlock AI insights, financials, peers and live data on Advik Laboratories Ltd. and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Advik Laboratories Ltd.ADVIKLA | ₹4 Cr | — | — | — | — | — | — | — |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2026
Financials
Advik Laboratories Ltd.
BSE: ADVIKLA · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Advik Laboratories Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
MPS Pharmaa Limited is an Indian pharmaceutical company engaged in the manufacturing and marketing of diverse pharmaceutical formulations, including ethical, generic, and over-the-counter products. Its portfolio covers therapeutic segments such as antibacterials, analgesics, and nutritional supplements, produced at its facility in Sohna, Haryana.
Business Model
The company generates revenue through the production and distribution of pharmaceutical formulations in various forms, including tablets, capsules, and liquids. It focuses on domestic distribution while actively exploring export opportunities in emerging markets.
Management Commentary
The company has recently undergone corporate restructuring and a name change to better align its operations with evolving business strategies within the healthcare sector.
Growth Outlook
Growth is expected to be driven by the company's strategic realignment and the expansion of its product reach into emerging international markets. Continued focus on its core therapeutic segments remains central to its operational strategy.
Key Risks
- Regulatory Compliance. The company faces risks associated with maintaining national regulatory standards at its manufacturing facility.
- Market Competition. The Indian pharmaceutical sector is highly competitive, which may impact pricing power and market share for generic and OTC products.
- Execution Risk. Successful implementation of the recent corporate restructuring is critical to achieving the company's long-term strategic objectives.
Start your research today
Unlock AI insights, financials, peers and live data on Advik Laboratories Ltd. and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026